Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Videos|November 27, 2014
Pharmacy Times Asks a Burmans Pharmacist: How Are You Raising Awareness for Pharmacy Services?
Vince Canzanese, RPh, director of compounding at Burmans Pharmacy, says the independent pharmacy raises awareness about its services by being involved in the Brookhaven, Pennsylvania, community.
Advertisement
Vince Canzanese, RPh, director of compounding at Burmans Pharmacy, says the independent pharmacy raises awareness about its services by being involved in the Brookhaven, Pennsylvania, community.
“The best way that we are able to advise patients is to get out and see our medical providers,” he says.
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5